NCT06697301ClinicalTrials.gov ↗
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Active, not recruitingPhase IIIEN originalBreast cancerHormone receptor positive (HR+)Metastatic / advanced
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
NCT06216301ClinicalTrials.gov ↗
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
NCT07700979ClinicalTrials.gov ↗
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
NCT07623174ClinicalTrials.gov ↗
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body. This cancer can be hard to treat because it can behave differently from one person to another. Over time, treatments may stop working, and side effects can build up. In later treatment stages, there are only a few standard medicine options available. Because of this, studies often look at both how long people live and how treatment affects quality of life. The main aim of this study is to see how long adults in Poland with mCRC live without their cancer getting worse (progression-free survival or PFS) when they receive fruquintinib after at least two previous treatments. Fruquintinib (TAK 113) is a medicine taken by mouth that is designed to slow tumor growth. Other aim is to find out how long adults in Poland with mCRC live while being treated with fruquintinib (overall survival or OS). The study also wants to record how fruquintinib is used in routine care in adults with mCRC in Poland (for example when treatment starts, changes in doses, and how long treatment continues). Another aim is to learn about people with mCRC, such as their medical history and past treatment as well as their quality of life while they are in the study. The study will look at data already existing in the participants' medical charts.
About the trial
This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi ER+/HER2- potwierdzony badaniami.
- •Choroba widoczna w badaniach obrazowych lub co najmniej jedna zmiana kostna.
- •Kobiety w okresie menopauzy muszą spełniać warunki protokołu. Kobiety przed menopauzą i mężczyźni muszą stosować terapię LHRH.
- •Choroba postępująca mimo wcześniejszego leczenia (1-2 terapie hormonalne, maksymalnie 1 chemioterapia).
- •Ogólny stan zdrowia dobry (ECOG 0-1).
- •Dobre wyniki badań narządów.
✗ Disqualifies
- •Wcześniejsze leczenie lekami podobnymi do SERD, terapiami ukierunkowanymi na ER lub inhibitorami PI3K/AKI/mTOR.
- •Udział w innym badaniu w ciągu ostatnich 28 dni.
- •Przyjmowanie leków wpływających na metabolizm leków badanych w krótkim czasie przed rozpoczęciem leczenia.
- •Zaawansowane, objawowe przerzuty do narządów zagrażające życiu.
- •Aktywne przerzuty do mózgu, zapalenie opon mózgowych.
- •Ciężkie choroby serca lub problemy z pracą serca.
- •Ciąża lub karmienie piersią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (57)
The First Affiliated Hispital of Bengbu Medical University
Bengbu, China
Anhui Provincial Cancer Hospital
Hefei, China
The First Affiliated Hispital of Anhui Medical University
Hefei, China
Maanshan People's Hospital
Maanshan, China
Beijing Cancer Hospital
Beijing, China
The First Medical Center of PLA Ggeneral Hospital
Beijing, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Fujian Provincial Hospital
Fuzhou, China
Gansu Provincial Cancer Hospital
Lanzhou, China
Guangdong Maternal and Child Health Hospital
Guangzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Zhongshan City People's Hospital
Zhongshan, China
Guangxi Medical University Cancer hospital
Nanning, China
First Hospital Of Qinhuangdao
Qinhuangdao, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Harbin Medical University Cancer Hospital
Harbin, China
Anyang Tumor Hospital
Anyang, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, China
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Hubei Cancer Hospital
Wuhan, China
Wuhan University Zhongnan Hospital
Wuhan, China
Xiangyang Central Hospital
Xiangyang, China
The First PEOPLE'S HOSPITAL OF CHANGDE CITY
Changde, China
Hunan Cancer Hospital
Changsha, China
Xiangya Hospital of Central South University
Changsha, China
The Central Hospital of Yongzhou
Yongzhou, China
Jiangsu Cancer Hospital
Nanjing, China
Nanjing Drum Tower Hospital
Nanjing, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Xuzhou Central Hospital
Xuzhou, China
Jiangxi Cancer Hospital
Nanchang, China
Jilin Cancer Hospital
Changchun, China
The First Hospital of Jilin University
Changchun, China
The Second Hospital of Dalian Medical University
Dalian, China
The First Affiliated Hospital of JINZHOU Medical University
Jinzhou, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Hospital of China Medical University
Shenyang, China
First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
Baoji Central Hospital
Baoji, China
Binzhou Medical University Hospital
Binzhou, China
Shandong First Medical University and Shandong Academy of Medical Sciences
Jinan, China
Linyi Cancer Hospital
Linyi, China
Linyi People'S Hostipal
Linyi, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Weifang People'S Hospital
Weifang, China
Weihai Municipal Hospital
Weihai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Shanghai General Hospital
Shanghai, China
Sichuan Cancer Hospital
Chengdu, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Zhejiang Cancer Hospital
Hangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Ningbo Medical Center Lihuili Hospital
Ningbo, China
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.